Kristine Kucera, PA-C, MPAS, DHS Psoriatic Arthritis (PsA) affects up to one third of people with psoriasis (PsO). Evidence indicates that diagnosis of PsO may precede the diagnosis of PsA by up to a decade. Currently, most cases of PsA are diagnosed based on...
As biosimilar products make their way into the field of dermatology, the latest Dermalorian™ Webinar provided a closer look at these agents and their potential role in patient care. Leigh Ann Pansch, MSN, FNP-BC, DCNP, of DOCS Dermatology in Cincinnati, OH, and T.J....
Kristine Kucera, PA-C, MPAS, DHS The first interchangeable biosimilar for AbbVie’s Humira (adalimumab) officially entered the US market this month. Cyltezo (adalimumab-adbm) from Boehringer Ingelheim is now commercially available. As a reminder, biosimilars...
Kristine Kucera, PA-C, MPAS, DHS Treating pediatric patients with inflammatory skin disease often can be challenging. Without published treatment guidelines, clinicians may be uncomfortable prescribing methotrexate (MTX) in this population. To address this...
Listen NOW: A Diversity of Diagnoses, Part 2 A new episode of the Dermalorian Podcast Series is now live. In the second of a 2-part series, Ted Rosen, MD continues his focus on systemic diseases in skin of color. He addresses the diagnosis and management of systemic...
Join us September 30, 2023 in Dallas, Texas and November 4, 2023 in Scottsdale, Arizona DEF Biologic and Small Molecule NP/PA CME Bootcamps (Bootcamps) are coming back in-person! Join us September 30, 2023 in Dallas, Texas and November 4, 2023 in Scottsdale, Arizona...
